GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Analysis AS (FRA:8V8) » Definitions » Notes Receivable

Genetic Analysis AS (FRA:8V8) Notes Receivable : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Genetic Analysis AS Notes Receivable?

Genetic Analysis AS's Notes Receivable for the quarter that ended in Dec. 2023 was €0.00 Mil.


Genetic Analysis AS Notes Receivable Historical Data

The historical data trend for Genetic Analysis AS's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Analysis AS Notes Receivable Chart

Genetic Analysis AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
- - - - -

Genetic Analysis AS Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Genetic Analysis AS Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Genetic Analysis AS Notes Receivable Related Terms

Thank you for viewing the detailed overview of Genetic Analysis AS's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Analysis AS (FRA:8V8) Business Description

Traded in Other Exchanges
Address
Kabelgata 8, Oslo, NOR, 0580
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering innovative diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Genetic Analysis AS (FRA:8V8) Headlines

No Headlines